Karyopharm Therapeutics KPTI Cash Flow Statement (2012-2026)

NASDAQ KPTI
$0.02 -0.02 (-56.50%)
At close: Nov 10, 2026 · 4:00 PM EST
Reported Financials

Karyopharm Therapeutics Quarterly Cash Flow Statement

Periods 56 quarters
Latest Jun 2026

Karyopharm Therapeutics reported cash from operations of -$24.93M and free cash flow of -$24.93M for the quarter ended Jun 2026, down 33.3% year over year. This cash flow statement covers 56 quarters of results from Sep 2012 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Sep2012 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-51.81M38.72M-41.40M-49.06M-36.32M-38.51M-34.13M-32.63M-34.51M-41.84M-37.36M23.79M-32.07M-30.78M-23.46M-37.25M-33.13M-102.20M-67.02M
Depreciation and DepletionDep. & Depletion
0.19M0.14M0.18M0.15M0.18M0.11M0.29M0.08M0.08M0.08M0.09M0.09M0.08M0.08M0.08M0.08M0.12M0.02M0.01M0.00M
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges
0.20M0.20M0.20M0.20M0.20M0.21M0.20M0.19M0.21M0.22M0.21M1.40M2.41M2.36M2.57M2.72M2.81M2.45M2.36M2.56M
Depreciation & Amortization (CF)Dep. & Amort.
0.19M0.14M0.18M0.15M0.18M0.11M0.29M0.08M0.08M0.08M0.09M0.09M0.08M0.08M0.08M0.08M0.12M0.02M0.01M0.00M
Share-based CompensationStock Comp.
7.42M6.87M7.34M15.09M6.80M6.17M5.39M6.06M5.08M5.18M5.41M5.41M4.18M3.86M3.78M3.78M2.80M3.90M1.93M
Gains from Investment SecuritiesGains Investment
-0.51M0.00M0.00M0.28M14.34M4.00M10.35M19.97M-2.04M-7.33M-9.89M16.48M-32.04M
Asset Writedowns and ImpairmentWritedown
0.20M
Other non-cash itemsOther Non-Cash
7.20M-0.18M0.00M0.00M0.00M0.00M0.00M-44.70M62.37M
Change in Working Capital
Change in ReceivablesChange Receivables
0.87M3.75M2.50M-1.51M3.97M0.14M-11.89M-2.92M5.64M-10.96M4.12M6.91M-6.22M-1.01M4.48M-2.31M-1.06M-5.70M-2.82M6.51M
Change in InventoryChange Inventory
-0.12M0.08M-0.23M-0.40M0.78M-0.03M-0.40M-0.16M-0.57M-0.06M-0.27M0.71M1.20M0.07M0.03M0.22M-1.03M0.07M-0.44M0.40M
Change in Account PayablesChange Payables
-1.43M0.72M1.84M-1.75M-0.88M1.96M6.27M-6.76M-1.34M2.18M1.91M-2.23M2.99M-0.68M0.77M-3.28M2.80M-1.39M0.28M3.38M
Change in Accrued ExpensesChange Accrued Exp.
12.09M3.68M-9.39M-2.18M-0.05M2.09M-9.41M5.34M3.30M4.78M-4.86M0.06M2.55M6.45M-0.41M8.58M9.45M1.44M-0.26M3.77M
Change in Other Operating AssetsOther Assets Change
-3.15M21.39M15.20M-1.15M-7.31M-2.64M-2.00M-0.67M-4.39M-1.58M3.12M-1.13M-0.75M0.80M-2.37M-2.43M-0.62M-0.04M-0.80M-1.27M
Change in Other Operating LiabilitiesOther Liabilities Change
-0.48M-0.21M-0.54M-0.55M-0.57M-0.66M-0.68M-0.70M-0.72M-0.77M-0.79M-0.81M-0.83M3.48M0.26M0.22M-0.70M-0.22M-0.23M-0.24M
Other Working Capital ChangesOther WC Changes
2.67M-21.60M-15.74M0.60M6.74M1.97M1.32M-0.04M3.67M0.82M-3.91M0.32M-0.08M2.69M2.63M2.65M-0.08M-0.18M0.57M1.03M
Cash from OperationsCash from Ops.
-23.96M25.48M-59.20M-35.14M-28.37M-26.84M-18.91M-25.70M-29.53M-18.59M-43.73M-38.50M-19.45M-25.81M-38.98M-18.70M-5.86M-11.83M-22.73M-24.93M
Investing Activities
Capital ExpendituresCapex
0.01M0.21M0.08M0.04M0.20M-0.05M
Change in Property, Plant and EquipmentChange in PP&E
-0.01M-0.21M-0.08M-0.04M-0.20M0.05M
Change in IntangiblesChange Intangibless
-0.50M
Purchase of InvestmentsInvestments Purchased
10.50M35.54M63.48M29.90M97.10M60.33M36.19M46.07M16.56M31.61M4.90M20.81M1.51M
Sale and Maturity of InvestmentsInvestments Sold
37.93M30.48M21.58M26.88M41.61M31.80M27.94M57.36M38.38M43.40M53.74M56.17M28.28M16.25M15.29M18.29M4.81M5.00M3.20M
Other Investing Activities (as filed)Other investing (as filed)
Cash from Investing ActivitiesCash from Investing
21.43M30.77M-14.04M-36.60M11.67M-65.30M-32.39M21.17M-7.69M26.84M21.94M51.26M7.47M14.80M15.29M18.29M4.81M5.00M3.20M-10.04M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance
27.25M
Net Long-Term Debt Issued (Repaid)Net LT Debt
27.25M
Net Debt Issuances and RepaymentsNet Debt Issuance
27.25M
Change in Capital Stock
Common Stock IssuedStock Issued
0.02M0.90M30.78M1.31M5.80M155.84M0.86M0.26M0.68M0.41M20.23M0.57M
Net Shares Issued and RepurchasedNet Shares Issued
0.02M0.90M30.78M1.31M5.80M155.84M0.86M0.26M0.68M0.41M20.23M0.57M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
0.02M0.90M30.78M1.31M5.80M155.84M0.86M0.26M0.68M0.41M20.23M0.57M
Other financing activities (as filed)
-6.46M-0.43M-1.47M
Cash from Financing ActivitiesCash from Financing
0.02M0.90M30.78M1.31M5.80M155.84M0.86M0.26M0.68M29.69M49.80M-0.90M
Additional items
Exchange Rate EffectFX Effect
0.24M-0.14M-0.09M-0.45M-0.07M0.13M-0.05M-0.03M-0.05M0.09M-0.02M-0.01M0.04M-0.02M0.01M0.01M0.00M0.01M0.00M0.00M
Change in Cash
-2.27M57.01M-42.54M-70.88M-10.97M63.83M-51.34M-3.69M-37.27M8.61M-21.80M53.72M-11.94M-10.35M-23.69M-0.05M-1.05M22.87M30.28M-35.87M
Ending Cash Balance
197.45M136.89M53.19M62.81M60.89M
Free Cash FlowFCF
-23.96M25.27M-59.28M-35.14M-28.41M-26.84M-18.91M-25.70M-29.53M-18.59M-43.92M-38.50M-19.45M-25.76M-38.98M-18.70M-5.86M-11.83M-22.73M-24.93M
Net Cash FlowNCF
-2.51M57.14M-42.45M-70.43M-10.90M63.70M-51.30M-3.67M-37.22M8.52M-21.79M12.76M-11.98M-10.33M-23.70M-0.41M-1.06M22.86M30.27M-35.87M
Interest Paid
2.59M2.59M2.59M2.93M8.54M5.65M5.14M5.53M

Karyopharm Therapeutics Cash Flow Statement API

Pull Karyopharm Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=KPTI&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY